

Evidence for complex interplay between quorum sensing and antibiotic resistance in *Pseudomonas aeruginosa*

Rakesh Sikdar and Mikael H. Elias¹

Department of Biochemistry, Molecular Biology and Biophysics and Biotechnology Institute,
University of Minnesota, Saint Paul, MN 55108, USA.

¹To whom correspondence should be addressed. Address: University of Minnesota,
Biotechnology Institute, 158 Gortner Laboratory of Biochemistry, 1479 Gortner Ave, Saint Paul,
MN 55108.
Email: mhelias@umn.edu.

Quorum sensing (QS) is a cell-density-dependent, intercellular communication system mediated by small diffusible signaling molecules. QS regulates a range of bacterial behaviors, including biofilm formation, virulence, drug resistance mechanisms, and antibiotic tolerance. Enzymes capable of degrading signaling molecules can interfere in QS - a process termed quorum quenching (QQ). Remarkably, previous work reported some cases where enzymatic interference in QS was synergistic to antibiotics against *Pseudomonas aeruginosa*. The premise of combination therapy is attractive to fight against multidrug-resistant bacteria, yet comprehensive studies are lacking. Here we evaluate the effects of QS signal disruption on the antibiotic resistance profile of *P. aeruginosa* by testing 222 antibiotics and antibacterial compounds from 15 different classes. We found compelling evidence that QS signal disruption does indeed affect antibiotic resistance (40% of all tested compounds; 89/222), albeit not always synergistically (not synergistic for 48% of compounds with an effect (43/89)). For some tested antibiotics, like sulfathiazole and trimethoprim, we were able to relate the changes in resistance caused by QS signal disruption to the modulation of the expression of key genes of the folate biosynthetic pathway. Moreover, using a *P. aeruginosa*-based *Caenorhabditis elegans* killing model, we confirm that enzymatic QQ modulates the effects of antibiotics on *P. aeruginosa*'s pathogenicity *in vivo*. Altogether, these results show that signal disruption has profound and complex effects on the antibiotic resistance profile of *P. aeruginosa*. This work suggests that combination therapy including QQ and antibiotics should not be discussed globally but rather in case-by-case studies.

IMPORTANCE

Interference in bacterial Quorum Sensing (QS) is a promising approach to control microbial behavior. Of particular interest is the potential of this strategy to reduce biofilms and virulence of antibiotic resistant strains. Interestingly, several studies report synergistic interactions between antibiotic treatments and interference in QS. However, it is unclear whether this is a generality, let alone the molecular mechanisms underlying the observed synergies. Here, we provide a comprehensive description of combination treatment in the model organism, opportunistic human pathogen *P. aeruginosa*. Screening > 200 antimicrobials, and combining them to QS signals and disruption strategies, we show that there is no systematic synergy between these approaches *in vitro*, as well as *in vivo*, in a *C. elegans* infection model. Altogether, this work shows that QS has complex connections to the antibiotic resistance profile of *P. aeruginosa*, and that combination treatment should not be discussed globally, but rather in case-by-case studies.

INTRODUCTION

Antibiotic resistance is reported to be rapidly rising, possibly partly due to the overuse of antibiotics in medical, agricultural, and industrial applications [1-3]. This risk may have increased during the COVID-19 pandemic and the increased use of antibiotics to prevent secondary bacterial infections in hospitals [4]. Pathogenic bacteria that are relevant in human diseases, such as *Pseudomonas aeruginosa*, can be resistant to numerous antibiotic treatments [5]. It is associated with 10% of nosocomial infections [6] and is the main cause of mortality and morbidity in a debilitating genetic disease like Cystic Fibrosis in humans [7]. It is listed among the top priority pathogens by the WHO for immediate R&D of new antimicrobials [8]. *P. aeruginosa* shows a remarkable ability to adapt to a wide range of environmental niches due to its high genome plasticity [9,10]. Interestingly, the virulence of *P. aeruginosa*, like many other pathogenic microbes, is regulated by a chemical communication system termed Quorum Sensing (QS) [11]. Consequently, interference in QS signaling is appealing to control microbial pathogens.

Numerous bacteria use QS for communication: they produce, secrete, sense, and respond to small diffusible signaling molecules known as AutoInducers (AIs). One main class of autoinducers is autoinducer-I or *N*-AcyL Homoserine Lactones (AHLs). AHL-based QS circuits are reported to regulate the expression of up to 6% of bacterial genes [12] and to modulate bacterial behaviors critical for their pathogenicity, such as virulence factor production, drug resistance, toxin production, motility, and biofilm formation, in a cell density-dependent manner [13].

P. aeruginosa has three interwoven QS signaling circuits with overlapping genetic targets - namely LasIR, RhIIR, and *Pseudomonas* Quinolone Signal (PQS) in a top-to-bottom order of hierarchy [14,15]. They produce, detect, and respond to autoinducer molecules *N*-3-oxo-dodecanoyl-*L*-Homoserine Lactone (3oC12-HSL), *N*-butyryl-*L*-Homoserine lactone (C4-

HSL) and alkyl-quinolones respectively. This sophisticated QS circuitry enables this bacterium to be a versatile and opportunistic pathogen that can adapt to a variety of environmental conditions in the host tissue and forms a robust biofilm that is difficult to disperse [16,17].

The antibiotic resistance of *P. aeruginosa* stems from several intrinsic, acquired, and adaptive mechanisms – as elaborated in the following Reviews [5,18,19]. These mechanisms can be three-fold - (i) Chemical modification of antibiotics using enzymes such as β -lactamases [20], aminoglycoside modifying enzymes [21], 16s rRNA methylases [22]; (ii) Modification of biofilm structure (extracellular polymeric substances) [23], membrane physiology (outer membrane permeability, LPS modification) [24] and/or surface porins (OprF, OprD, and OprH) to reduce antibiotic permeability [25]; (iii) Expression of multidrug efflux pumps (MexAB-OprM, MexCD-OprJ, MexEF-OprN, and MexXY-OprM) to secrete the antibiotics out of the cell [19], (iv) Altering the expression and/or characteristics of genes and proteins targeted by antibiotics (e.g. DNA gyrases, folate biosynthetic pathway genes) [22] and (v) utilizing global stress response systems (two-component signaling systems, e.g. PhoPQ, CprRS, ParRS) and phenotypic modifications (swarming and surfing motility, LPS modifications) to adapt to the antibiotic-mediated stress [26-28]. Many of these mechanisms may be regulated by QS regulation [18,19] and therefore antibiotic resistance and QS are possibly interconnected. In support of this hypothesis, some previous studies have highlighted potential synergistic effects between antibiotic treatments and interference in QS [29-36] yet a comprehensive investigation is lacking.

Numerous enzymes capable of hydrolyzing AHLs were isolated and characterized [13,37]. Lactonases, enzymes that hydrolyze and open the lactone ring of AHLs, have been enzymatically and structurally well-studied [38,39]. Well-characterized representatives from the Phosphotriesterase-Like Lactonase (PLL) family include VmoLac [40], SisLac [41], PPH [42] or SsoPox [43-45], as well as representatives from the Metallo- β -lactamase Lactonase (MLL) such as MomL [46], AiiA [47], AaL [48] or GcL [49]. By hydrolyzing AHLs, lactonases interfere in QS,

a process termed Quorum Quenching (QQ). QQ enzymes were shown to reduce the virulence of *P. aeruginosa* both *in vitro* and *in vivo* [46,50-58]. As *P. aeruginosa* utilizes C4-HSL and 3-oxo-C12 HSL-based QS signaling circuits, the AHL preference of the QQ enzyme is important as it may quench either or both LasIR and RhIR QS circuits. Moreover, recent studies showed that the substrate specificity of the QQ enzyme affected proteome profiles, virulence factors expression, virulence, and biofilm formation in *P. aeruginosa* [56,59].

In this study, we used two QQ lactonases with distinct substrate specificity, SsoPox [43] and GcL [49], to evaluate the effects of AHL signal disruption on the antibiotic-resistance profile of *P. aeruginosa*. We observed that signal disruption has complex effects on antibiotic resistance that are dependent on the antibiotic/antimicrobial compound and the QQ enzyme used. We confirmed key observations in independent assays. For the antibiotics sulfathiazole and trimethoprim, we provide evidence that changes in key genes regulation due to interference in QS signaling are responsible for the observed modulation of antibiotic resistance using quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR). Lastly, we demonstrate that these effects on antibiotic sensitivity of *P. aeruginosa* can translate *in vivo*, in a *Caenorhabditis elegans* killing assay.

Materials and Methods

Reagents, *Pseudomonas* strains, and growth conditions. *Pseudomonas aeruginosa* strain UCBPP-PA14 [60], designated as PA14 throughout this article, is used in all experiments and maintained in the laboratory following standardized protocols [61]. PA14 was cultured in either Miller's Luria-Bertani (LB) broth (BD Difco, #244610), LB-agar plates (BD Difco, #244510), or in a peptone-based proprietary growth media – GN IF-10A inoculating fluid (Biolog, #72264). Unless otherwise mentioned, all cultures were grown at 37°C with liquid cultures shaking at 250 rpm. All phenotype microarray plates – PM11C (#12211), PM12B (#12212), PM13B (#12213), PM14A (#12214), PM15B (#12215), PM16A (#12216), PM17A (#12217), PM18C (#12218), PM19 (#12219) and PM20B (#12220) and 100x Dye Mix A (#74221) were purchased from Biolog (Hayward, CA). *N*-butyryl-*L*-Homoserine lactone designated as C4-HSL (#10007898) and *N*-3-oxo-dodecanoyl-*L*-Homoserine lactone designated as 3oC12 HSL (#10007895) were purchased from Cayman Chemical Company (Ann Arbor, MI) and dissolved in 100% DMSO just before use. All other chemicals including antibiotics were of at least reagent grade and were purchased from either Millipore Sigma (Burlington, MA) or Fisher Scientific (Hampton, NH).

Lactonase production, purification, and quantitation. Production of the inactive SsoPox mutant 5A8 [62], SsoPox W263I [45] and GcL [49] in *Escherichia coli* strain BL21(DE3) was performed as previously described [44,49,59,63]. All lactonase preparations used in this study were made in buffer (PTE) composed of 50 mM HEPES pH 8.0, 150 mM NaCl, 0.2 mM CoCl₂, sterilized by passing through a 0.2µ filter, and stored at 4°C until use.

Preparation of antibiotic stocks. Antibiotic stocks were prepared just before use by dissolution in deionized water (Nafcillin sodium, Azlocillin sodium, Colistin sulfate, Sulfathiazole sodium, Sulfadiazine sodium, D-cyclo-serine, Carbenicillin disodium, and Procaine hydrochloride), in 100% DMSO (Oxacillin sodium, Coumarin, Trimethoprim, and Carbonyl

cyanide 3-chlorophenylhydrazone), in 0.1N HCl (Norfloxacin) or 1N NaOH (Ofloxacin). Antibiotic stocks were sterilized by passing through a 0.2 μ filter.

Biolog Phenotype MicroArray™ experiments. These experiments were conducted using a modification of a standard protocol obtained from Biolog Inc (Dr. Barry Bochner, direct communication). Phenotype MicroArray™ (PM) microplates allow for the testing of a range of antibiotics, inorganic salts, and bacteriostatic/bactericidal compounds (10 plates, labeled PM11 through PM20: each containing 24 compounds). Each tested compound is present at 4 concentrations, yet the precise concentration value is not disclosed by Biolog. Therefore, these MicroArrays provide a qualitative estimate of microbial sensitivity. The system is designed to use a proprietary peptone-based growth media – GN IF-10A to be supplemented with a proprietary tetrazolium redox dye mix. The dye is reduced to purple-colored formazan products (λ_{abs} 590 nm) due to NADH production (a sensitive indicator of respiration) by metabolically active cells [64,65]. This colorimetric reaction is monitored and recorded by a spectrophotometer at specific time intervals to generate a kinetic response curve mirroring microbial growth that can be further quantitated into parameters such as lag, slope, and area under the curve [66].

A single colony of PA14, picked from freshly streaked LB-agar plates, was inoculated in 2 mL LB media containing appropriate treatments (50 μ g/mL lactonases or *N*-acyl homoserine lactones at a final concentration of 10 μ M) and grown at 37°C/250 rpm until cells reach early log phase of growth ($\text{OD}_{600} \sim 0.2 - 0.3$). Cultures were then harvested by centrifugation (5000g for 3 min) and washed three times with Biolog IF-10A media (1.2x GN IF-10A inoculating fluid diluted to 1x using autoclaved deionized water and containing 1x Biolog dye mix A). Washed cells were resuspended in Biolog IF-10A media at an OD_{750} of ~ 0.05 . A final inoculum solution is made by diluting the washed cells 1:100 into fresh Biolog IF-10A media containing the similar treatment as above (50 μ g/mL lactonases or *N*-acyl homoserine lactones at a final concentration of 10 μ M). 100 μ L of the final inoculum solution was dispensed

into each well of a 96 well Phenotype MicroArray microplate and overlaid with 20 μ L sterile light mineral oil (Fujifilm Irvine #9305) to limit evaporation. Antibiotic-free Growth of PA14 with 50 μ g/mL SsoPox 5A8 for control purposes was carried out on a half-area sterile 96-well microplate (Corning #3696) to mimic the physical dimensions of Biolog PM microplates, using a similar protocol as above. The microplate was then incubated with a lid in a BioTek Epoch2 microplate spectrophotometer at 37°C with linear shaking at 300 rpm for 24 hrs. OD₅₉₀ (absorbance of formazan, as discussed earlier) and OD₇₅₀ (for cell turbidity) were measured for each well every 15 min. The [OD₅₉₀ – OD₇₅₀] values plotted against the time of growth corresponds to the growth curve of PA14 and the area-under-the-curve (AUC), calculated with the BioTek Gen5 (v2.9) software corresponds to the total growth of PA14 over 24 h.

Data analysis and presentation for the Biolog Phenotype MicroArray experiments.

Raw area-under-the-curve (AUC) data from the BioTek Gen5 software was analyzed and processed initially in Microsoft Excel worksheets before final analysis in GraphPad Prism 8. AUC values less than 1000 were found to be baseline noise and were discarded from subsequent analysis. Each antibiotic or antibacterial compound in the MicroArrays has 4 gradually increasing dosages (undisclosed by Biolog) in 4 horizontally adjacent microwells (denoted as “Concentration 1” through “Concentration 4” in **Fig. S1A, B - S5A, B**, with the leftmost microwell containing the lowest dose (Concentration 1) and the rightmost microwell containing the highest dose (Concentration 4). The AUC data was used to compare the treatments by normalizing each treatment (SsoPox W263I, GcL, C4-HSL, 3oC12-HSL) to the control (SsoPox 5A8; inactive lactonase) using the following formula:

$$\text{Normalized Growth (\%)} = \frac{\text{AUC for treatments}}{\text{AUC for control (SsoPox 5A8)}} * 100$$

We present the treatment-dependent normalized results for all the 222 unique antibiotics and antibacterial compounds, organized according to their dosage (Concentration 1-4) in the form of graded heatmaps (white-red-black color schema) in **Fig. S1-S5**. An additional heatmap strip with a green-black color scheme is overlaid on the right, which represents the sensitivity of PA14 to the indicated concentration of the compounds. We term it as the “relative resistance score” of PA14 against that compound at that indicated concentration, calculated by the following formula:

$$\text{Relative Resistance Score} = \frac{\text{AUC of PA14 growth with compound and SsoPox 5A8}}{\text{AUC of PA14 growth with SsoPox 5A8 only}} * 100$$

A relative resistance score of 100% means that PA14 is completely resistant to the tested compound and that its growth is unaffected by the compound. All heatmaps were generated and processed in GraphPad Prism 8. Shorter synonyms of the following compound names used by Biolog in the MicroArrays were obtained from PubChem (<https://pubchem.ncbi.nlm.nih.gov/>) and used in the heat maps (**Fig. 1, 2, and S7**) for aesthetic purposes and indicated in braces - Methyltrioctylammoniumchloride (Methyltrioctyl-NH₄Cl); 5,7-Dichloro-8-hydroxyquinoline (Chloroxine), Sodium pyrophosphate decahydrate (Sodium pyrophosphate); 1-Chloro-2,4-dinitrobenzene (Chlorodinitrobenzene); 5-Nitro-2-furaldehyde semicarbazone (Nitrofurazone); 1-Hydroxypyridine-2-thione (Pyrithione); 3, 4-Dimethoxybenzyl alcohol (Veratrole alcohol) and L-Glutamic-g-hydroxamate (Glutamine hydroxamate).

Screening of the data from the Biolog Phenotype MicroArray experiments. Results from the MicroArrays (**Fig. S1-S5**) were filtered, and this study focuses on compounds meeting all the following three criteria – (i) A differential change in PA14 growth is observed between the lactonase (SsoPox W263I and GcL) and AHL (C4-HSL and 3oC12-HSL) treatments at a given concentration. (ii) At this concentration, the antibiotic or antibacterial compound alters the

growth of PA14 by at least 25% in at least one of the treatments (lactonase or AHL) compared to the control (5A8). (iii) The relative resistance score of PA14 against that antibiotic or antibacterial compound at that concentration should be 70% or lesser. These three filtering criteria eliminate compounds for which weak changes are observed and allow for the identification of molecules for which the resistance of PA14 is more likely to be regulated by QS signaling (**Fig. 1 and 2**). The first filter is self-explanatory, *i.e.*, different outputs for QS and QQ treatment may mean that a biological pathway or mechanism regulated by QS is involved in the observed change in resistance. The second filter stems from the observation that changes below 25% did not robustly replicate in new culture experiments described in the following section. The third criterion is based on the fact that changes in resistance are more easily and robustly observed when the antibiotics treatment substantially reduces growth (**Fig. S1-S5**).

PA14 growth experiments with antibiotics. We replicated key observations from the phenotype MicroArray studies. For this purpose, we designed PA14 growth experiments using similar growth conditions on 96-well microplates. Growth, harvesting, and washing of PA14 were done similarly to described above. An inoculum solution is made by diluting the washed PA14 cells 1:100 into fresh Biolog IF-10A media. Sublethal concentrations of all the following tested antibiotics and antibacterial compounds were determined by performing dose-response experiments using a similar growth protocol as described above (**Fig. S8**). The compounds that we tested included – nafcillin (200 µg/mL), oxacillin (800 µg/mL), D-cyclo-serine (200 µg/mL), norfloxacin (0.25 µg/mL), ofloxacin (0.5 µg/mL), azlocillin (5 µg/mL), sulfadiazine (25 µg/mL), sulfathiazole (25 µg/mL), carbenicillin (50 µg/mL), trimethoprim (20 µg/mL), procaine (500 µg/mL), coumarin (500 µg/mL), carbonyl cyanide 3-chlorophenylhydrazone or CCCP (50 µg/mL) and colistin (0.1 µg/mL). The growth of PA14 against these compounds at indicated sublethal dosages in the presence of lactonases (SsoPox W263I or GcL, 50 µg/mL), inactive lactonase (SsoPox 5A8 mutant as control, 50 µg/mL), or pure exogenously added AHLs (C4-HSL or 3oC12-HSL, 10 µM) was determined similarly to the Phenotype MicroArray experiments but

conducted in replicates. 150 μ L of each set of supplemented inoculum solution was dispensed into at least 4 consecutive wells of a 96 well sterile non-binding polypropylene microplate (Corning #3879) and topped with 50 μ L sterile light mineral oil to prevent evaporation. The microplate was incubated and the growth of PA14 was recorded in a BioTek Epoch2 microplate spectrophotometer as described above.

Total RNA extraction. Overnight cultures of PA14 in LB media were diluted 1:100 into fresh LB and grown until OD₆₀₀ is ~ 0.3 - 0.4. The cultures were harvested by centrifugation (5,000g for 3 min), and washed thrice with Biolog IF-10A media (without dye mix A). Washed cells were re-suspended in Biolog IF-10A media (without dye mix A) at an OD₇₅₀ of ~0.05. The washed cells were diluted 1:100 into 2 mL fresh Biolog IF-10A media (without dye mix A) with or without antibiotics sulfathiazole (25 μ g/mL) or trimethoprim (20 μ g/mL) in polypropylene culture tubes (Corning #352059) and supplemented with 50 μ g/mL enzymes or 10 μ M (final) *N*-acyl homoserine lactones. Each condition was replicated 4 times. The cultures were incubated at 37°C for 22 h and shaken at 250 rpm. After incubation, the cultures were cooled on ice and the cells from 1 mL of culture were harvested by centrifugation (6000g for 5 min at 4°C). Cell pellets were frozen at -80°C until RNA extraction. Total RNA was extracted using the RNeasy mini kit (Qiagen #74104) following the manufacturer's instructions. During purification, residual genomic DNA contamination was removed by an on-column DNase digestion performed using the RNase-free DNase I kit (Qiagen #79254) following the manufacturer's protocol at 37°C for 1 hr. The quality and quantity of purified RNA were tested using the Take3 plates on a BioTek Synergy HTX microplate reader. All extracted RNA was stored at -80°C until use.

Quantitative Reverse Transcription Polymerase Chain Reaction (qRT-PCR). qRT-PCR was performed using the Power SYBR® Green RNA-to-CT™ 1-Step Kit (Thermo Fisher Scientific #4389986) on a StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific) following the manufacturer's instructions. RT-PCR grade water (Ambion #AM9935) was used for setting up all reactions. Primers for PA14 *folA*, *folP*, and *recA* genes (**Table S1**) were initially

characterized to determine optimal concentrations and efficiencies in qPCR reactions using the Thermo Fisher Scientific StepOne™ software v2.3. Total reaction volumes were 10 µL. Primer concentrations used were – *foIA* (100 µM forward and reverse primers), *foIP* (200 µM forward and reverse primers), and *recA* (100 µM forward and reverse primers). Appropriate qRT-PCR controls – no template, no primer, and no reverse-transcriptase controls were performed for each reaction set. A relative quantification approach was undertaken to determine the amounts of *foIA* and *foIP* mRNA in each reaction, by using *recA* as the endogenous control gene.

***Caenorhabditis elegans* liquid killing assays.** Some experimental conditions changes were required to adapt the PA14 antibiotic resistance study conditions to the *C. elegans* infection model, including the growth media and incubation temperature. Standardized liquid killing assay [67] requires a specific culture medium to co-incubate the nematodes with PA14 at a temperature not exceeding 25°C, as that would otherwise be lethal for the nematodes. We noted that the Biolog IF-10A medium is toxic to *C. elegans* upon prolonged incubation, but that the toxicity can be reduced significantly with dilution (data not shown). Therefore, a 1:1 dilution of IF-10A media (without dye mix A) in the M9W buffer was chosen. It increases the mortality of *C. elegans* by 10-30% compared to a standard *C. elegans* maintenance buffer such as M9W in a 24-48 h incubation period (data not shown). We note that other buffer media, such as S-basal, S-complete, or SK media [68] could not be used because they caused the precipitation of the IF-10A media upon mixing.

Growth of *C. elegans*. Strain SS104 [*glp-4(bn2)*] was obtained from the *Caenorhabditis* Genetics Center (CGC), University of Minnesota. The *glp-4(bn2)* mutation makes the nematodes incapable of producing offspring at temperatures greater than 20°C [69]. This is necessary to prevent the formation of progeny nematodes during the incubation period which will eventually hinder the downstream counting process. Nematodes were routinely maintained and cultured in the laboratory at 16°C on Nematode Growth Media (NGM) using standard protocols [68]. We modified a liquid killing assay protocol [67,68] for this study. Synchronization

of SS104 nematodes was performed by hypochlorite isolation of eggs from gravid adults. The eggs were washed and hatched in M9W medium for 24 h at 23°C to generate starved L1 larvae. Larvae were collected by centrifugation (1000g during 1min) and seeded on a 6 cm NGM-agar plate with a lawn of *E. coli* strain OP50 as food for the nematodes. The plate was incubated at 23°C for 48 h to generate a synchronized population of young adult nematodes. The nematodes were washed off the plate using M9W, followed by 6 subsequent wash steps interspersed with gravity-mediated settling of nematodes, and finally suspended in M9W. Work with *C. elegans* does not require IACUC approval.

Growth of bacteria. Overnight cultures of *E. coli* OP50 and *P. aeruginosa* PA14 in LB media were diluted 1:100 into fresh LB and grown until OD₆₀₀ is ~ 0.3 - 0.4. The cultures were harvested by centrifugation (5000g for 3 min), washed thrice with M9W, and resuspended in M9W at a final OD₆₀₀ of 0.3.

Assay conditions. Young adult SS104 nematodes were co-incubated with *P. aeruginosa* PA14 in a 1:1 mix of IF-10A media (without dye mix A) and M9W buffer for 24 hrs. at 23°C with antibiotics (5 µg/mL azlocillin, 200 µg/mL nafcillin or 25 µg/mL sulfathiazole) and lactonases (100 µg/mL) or AHLs (20 µM). All components of the assay were mixed in a sterile flat-bottom 96-well microplate (Sarstedt # 82.1581.001). Each well contained 200 µL of assay medium, composed of a mixture of M9W and Biolog IF-10A media (without dye mix A) at a ratio of 1:1, and supplemented with 10 µg/mL cholesterol, antibiotics, bacteria at a final OD₆₀₀ of 0.03, *C. elegans* (at least 20 - 50 young adult nematodes per well). For experiments with PA14 only, enzymes (100 µg/mL) or *N*-acyl homoserine lactones (20 µM) were also added. As a control experiment, young adult nematodes were incubated with *E. coli* OP50 in the same media without antibiotics and lactonases/AHLs for a similar duration. OP50 is used as a standard food source for *C. elegans* during its routine laboratory maintenance and propagation and therefore, mortality observed when the nematodes are incubated with OP50 is treated as a control observation. For wells with OP50, sterile PTE buffer was added as a proxy for enzymes. At least

3 replicates were performed for each condition that was tested. Due to the inherent variability in manually pipetting nematode suspensions [70], the number of nematodes dispensed in each well varied, but each well contained at least 20, and most wells contained 20 to 50 nematodes. The microplate was then sealed with gas-permeable Breathe-Easy Membranes (Diversified BioTech #BEM-1) and incubated in a humidified incubator at 23°C for 24 h with shaking (300 rpm). After a 24 hr co-incubation period, the nematodes were allowed to settle at the bottom of the wells by gravity. 100 μ L of media supernatant was discarded and the remaining 100 μ L containing the nematodes were transferred to unseeded 3.5 cm NGM-agar plates. The plates were sealed with parafilm and incubated at 23°C for a 24 hr recuperation period. The nematodes were then manually scored alive or dead under a microscope (Leica M165C) after touching them using a traditional worm pick [68].

Data Analysis. Experimental data is represented as a % of nematodes that are alive after the entire incubation period for each treatment condition.

Graphing and Analysis of Data. All data processing, analysis, and subsequent graphing is done either using Microsoft Excel or GraphPad Prism 8. Unpaired two-tailed t-tests with Welch's correction were used for determining statistical significance and calculated using GraphPad Prism.

Results and Discussion

The effect of QS signal disruption in *P. aeruginosa* was previously shown to be synergistic with some antibiotics, namely ciprofloxacin [29-31,35], ceftazidime [35] and gentamicin [29]. However, it remains unclear if this approach can be synergistic with all antibiotic therapies. To address this issue, we investigated if QQ can alter the global antibiotic resistance profile of *P. aeruginosa*. We used the Biolog Phenotype MicroArrays [66] to characterize the antibiotic-resistance profile of *P. aeruginosa* in the presence of QQ lactonases. While these MicroArrays have been previously used to study the metabolic characteristics of various *P. aeruginosa* strains under a range of conditions [66,71-76], or to study the chemical resistance in other bacteria [77-79] or mixed microbial communities [80], a comprehensive study of the antibiotic-resistance profile of laboratory strains of *P. aeruginosa* as a function of AHL signaling was not reported to our knowledge.

Screening with antimicrobials reveals that resistance is modulated by lactonase treatment

We quantified the growth of PA14 using 10 Phenotype MicroArrays (Biolog PM11 to PM20) containing a total of 222 unique antibiotics and antibacterial compounds, in the presence of 4 experimental treatments – two lactonases (SsoPox W263I, GcL) and two pure exogenously added AHLs (C4-HSL, 3oC12-HSL) – and 1 control treatment, the inactive lactonase SsoPox 5A8 mutant (**Fig. 1-2; Fig. S1-S5**). An increase in the growth of PA14 in the presence of antimicrobial compounds relates to an increase in *resistance* (or a decrease in *sensitivity*) against these compounds. Conversely, decreased growth relates to an increase in *sensitivity* (decrease in *resistance*) against these compounds. It is in this context that the terms “sensitivity” and “resistance” are used throughout this manuscript.

Growth patterns of PA14 in the presence of antibiotics or antibacterial compounds appear considerably altered with lactonases/AHLs, and these alterations are also a function of the concentrations of these compounds (**Fig. S1-S5**). As expected for most of the antibiotics and antibacterial compounds, the growth of PA14 decreased with the increasing concentration of the compounds. The whole screening results shown in **Fig. S1-S5** were reduced using a set of criteria described in the Methods section to focus on the most robust changes upon treatments. Compounds of particular interest are shown in **Fig. 1 and 2**.

Results shown in **Figs. 1, 2, S1-S5** show that the antibiotic sensitivity profile of PA14 is dependent on QS signaling. Indeed, these tested antibiotics and antibacterial compounds can be broadly classified into two major groups. The first group (**Fig. 1**) includes conditions where lactonase treatment suppresses and/or exogenous AHLs promote the growth of PA14. QQ increases the sensitivity (or decreases the resistance) of PA14 against this group of molecules. The second group of tested antibiotics and biocides shows the opposite trend (**Fig. 2**): for these molecules, the lactonase treatments promote and/or exogenous AHLs suppress the growth of PA14, suggesting that QQ decreases the sensitivity (or increases the resistance) of PA14. As expected, changes in sensitivity of PA14 are more easily observed at antibiotic concentrations that exhibited a lower relative resistance score (**Fig. S1-S5**), usually below 70%.

Among the tested compounds that did not reduce PA14 growth much (resistance score >70%), a change in growth upon treatment (>25% in at least one treatment compared to 5A8 control) was observed for 10 molecules (**Fig. S6**). The sensitivity of PA14 to all these 10 compounds was significantly increased by QQ lactonase treatment, as compared to the control. For example, in the presence of chlorhexidine, PA14 showed a 19% and 42% reduction in growth upon QQ with SsoPox W263I and GcL, respectively, and a 9% and 11% increase in growth upon the addition of C4-HSL and 3oC12-HSL, respectively, compared to SsoPox 5A8 treated control. These types of observations are likely outliers and are largely eliminated using our filtering criteria (discussed in Methods).

We used the lactonases SsoPox W263I and GcL for AHL signal disruption. These enzymes were enzymatically and structurally characterized in previous studies [43-45,49,59]. Specifically, SsoPox shows a strong AHL preference for long acyl chain AHL substrates (>C8) and low activity against C4-HSL. On the other hand, GcL exhibits broad substrate preference and hydrolyzes both C4-HSL and 3oC12-HSL with high proficiency. The difference in kinetic properties of these two enzymes was previously described [59]. Since *P. aeruginosa* simultaneously utilizes two QS circuits based on C4-HSL and 3-oxo-C12 HSL, these two lactonases with distinct specificities may differentially affect these circuits. Differential QQ with these enzymes was previously described and resulted in differential proteome profiles, virulence factors expression, virulence, and biofilm formation in *P. aeruginosa* [56,59].

To assess whether changes in antibiotic resistance would be sensitive to the differential quenching of AHL QS circuits, we focused on compounds for which robust resistance changes can be observed (see methods) and for which SsoPox W263I and GcL treatments show large differences (**Fig. S7**). For 27% of all tested compounds (60/222), changes in resistance upon lactonase treatment are unidirectional i.e., both lactonases either increase (32/60) or decrease (28/60) growth compared to control. Within these groups, some differences can be observed. For example, for a fraction of the compounds (5% of all tested compounds; 11/222), SsoPox W263I treatment resulted in >25 percentage points higher PA14 growth increase than GcL treatment (**Fig. S7**, top heat map panel). For another fraction (4.5% of all tested compounds; 10/222), GcL treatment yielded >25 percentage points higher PA14 growth compared to SsoPox W263I (**Fig. S7**, middle heat map panel). For another group of compounds (5.4% of all tested compounds; 12/222), treatment with both lactonases resulted in opposite changes in resistance, i.e. the change in the growth of PA14 was opposite with SsoPox W263I and GcL by >25% for at least one lactonase compared to 5A8 treated control (**Fig. S7**, bottom heat map panel). These observations suggest that the AHL-dependent changes in the resistance profile of PA14 may be sensitive to the AHL substrate specificity of the QQ lactonase.

Replication experiments show that interference in AHL signaling induces changes in resistance that are variable in sign and magnitude

Observations derived from the experiments with the Biolog Phenotype MicroArrays were replicated for some key candidate compounds. First, dose-response experiments against PA14 were performed (**Fig. S8**) and used to determine their sublethal concentration values. This was needed because of the proprietary conditions of Biolog MicroArrays. The results (**Fig. 4**) confirm that the antibiotic resistance profile of PA14 is dependent on AHL signaling. Similar to the screening experiment, the same two groups of compounds can be established – (i) antibiotics for which lactonases suppress and/or exogenous AHLs promote the growth of PA14 (e.g., nafcillin, oxacillin, D-cyclo-serine, norfloxacin, and ofloxacin) and (ii) antibiotics for which lactonases promote and/or exogenous AHLs suppress the growth of PA14 (e.g., azlocillin, sulfadiazine, sulfathiazole, and carbenicillin). Lactonase treatment increased the sensitivity of PA14 against nafcillin, oxacillin, D-cyclo-serine, and norfloxacin by up to 55%, 50%, 70% and 35% respectively, compared to control. On the contrary, lactonase treatment increased the resistance of PA14 against azlocillin, sulfadiazine, sulfathiazole, and carbenicillin by up to 176%, 73%, 215% and 362% respectively, compared to control. In the case of ofloxacin, no significant effect of lactonase treatment on PA14 sensitivity was observed. However, the addition of exogenous AHLs to stimulate QS increased the resistance of PA14 to ofloxacin by up to 23% compared to the control. These results suggest a complex relationship between QS and antibiotic resistance in PA14. For example, lactonase treatments and the addition of C4-HSL with antibiotics like sulfadiazine, sulfathiazole, and trimethoprim, increased the resistance of PA14 to these compounds by 25%, 15% and 28% respectively, compared to control (**Fig. 4**). This is not the case with 3oC12-HSL treatment, for which resistance of PA14 does not differ from control. Treatment with GcL increased the sensitivity and with C4-HSL increased the resistance of PA14 against trimethoprim by 21% and 28% respectively, compared to control

(Fig. 4). This is consistent with the lactonase substrate specificity, because GcL degrades C4-HSL proficiently (and SsoPox W263I does not), therefore GcL and addition of C4-HSL appear to show antagonistic effects.

For some compounds, including procaine and coumarin, the results are surprising: both lactonase and AHL treatments increase the sensitivity of PA14 against these compounds by up to 51% (**Fig S11**). Coumarin was previously reported to be an inhibitor of QS circuits and additional signaling pathways in *P. aeruginosa* [81,82], and this is expected to affect the results of our experiments. In the case of procaine, it was previously shown to enhance antibiotic resistance in *P. aeruginosa* by increasing the expression of the MexCD-OprJ and MexAB-OprM efflux pumps [83], and is therefore also likely to affect the outcome of our experiments.

Overall, most observations from these replicated experiments are consistent with results from the screening (**Fig. S9-S11**). However, some differences can be noted for a few compounds (e.g., ofloxacin, procaine, CCCP, colistin, and trimethoprim). These discrepancies likely originate from the sensitivity of QS-dependent regulations to growth conditions. The latter could not be exactly reproduced due to the proprietary composition of Biolog conditions. The fact that QS-dependent regulations are highly sensitive to growth conditions and treatment is illustrated by two different sublethal concentrations (150 and 200 $\mu\text{g/mL}$) of D-cyclo-serine (**Fig S12**). With 150 $\mu\text{g/mL}$ of D-cyclo-serine, lactonase treatments increased PA14 sensitivity by 9%, while it increased PA14 sensitivity up to 70% with 200 $\mu\text{g/mL}$ of D-cyclo-serine. Additionally, we note that this increased sensitivity may originate from the positive regulation of alanine racemase in *P. aeruginosa* by QS, a target of D-cyclo-serine (see Table S1 in ref [84] for studies conducted with strain PAO1).

Altogether, these experiments (**Fig. 1, 2, S1-S5**) show that: (i) AHL mediated QS signaling can significantly alter the antibiotic resistance profile of *P. aeruginosa*; and (ii) changes in resistance are variable in sign and magnitude, in ways that are not inferable from the properties of the tested antibiotics and antibacterial compounds.

The sign of the effect of lactonase treatment on resistance varies for the different tested antimicrobial groups

We classified the tested antibiotics and antibacterial compounds according to their type, class, or mode of action – namely aminoglycoside, antifolate, β -lactam cephalosporin, β -lactam penicillin, quinolone and fluoroquinolone, glycopeptide, macrolide and lincosamide, nitrofurans, polymyxin, quaternary ammonium salt, rifamycin, sulfonamide, tetracycline, and inorganic salt. Antibacterial compounds not fitting into any of these categories were labeled as unclassified organic compounds. Because the bacterial resistance mechanisms developed are often conserved and specific to certain antibiotic or antibacterial compounds, we hypothesized that observed changes may be shared by compound classes. This is corroborated by previous observations showing that QQ enzymes can alter the levels of proteins typically involved in antibiotic resistance in PA14 proteomics studies [59].

Consistently, we observe groups of molecules for which QQ lactonase treatment is either neutral or increases the sensitivity of PA14 (**Fig. 3**; i.e., antifolates, polymyxins, rifamycins, quinolones, fluoroquinolones, nitrofurans, macrolides, lincosamides, and quaternary ammonium compounds). We also observe groups of molecules for which QQ lactonase treatment is either neutral or decreases the sensitivity of PA14 (**Fig. 3**; sulfonamides, tetracyclines). Other groups, for which QS modulation can either increase or decrease resistance, include inorganic salts, an unclassified group of organic compounds, and the β -lactam group (penicillins and cephalosporins). We note that for most conditions, QS alteration resulted in no change in PA14 resistance. This may be caused by the fact that the involved pathways are unaffected by quorum quenching, and/or that the inherent resistance of PA14 against these compounds and the fact that tested concentrations were too low to sufficiently challenge PA14 growth. This is illustrated by the observed correlation between the relative resistance score and the magnitude of the observed modulations by QS alterations.

AHL signal disruption by lactonases led to exclusively increased sensitivity of PA14 to 40% of tested fluoroquinolones (2/5) on the Biolog Phenotype MicroArrays (**Fig. 3**). Fluoroquinolone antibiotics inhibit bacterial DNA synthesis by targeting DNA topoisomerases essential for DNA replication in bacteria – DNA gyrase (in Gram-negative bacteria) and topoisomerase IV (in Gram-positive bacteria) [85]. Typical mechanisms of resistance against this class of antibiotics involve antagonistic mutations in target topoisomerases, use of efflux pumps to secrete the drugs out of the cell, or reducing their membrane permeability through porins [86]. In the case of *P. aeruginosa*, the RND efflux pumps MexAB-OprM [87], MexCD-OprJ [88], and MexEF-OprN [89] were implicated in fluoroquinolone resistance. Here, the increased sensitivity of PA14 observed with lactonase treatment might be related to decreased OprM levels upon lactonase treatment as was previously reported [59]. Conversely, adding exogenous AHLs increases resistance to ofloxacin (**Fig. 4**). This is consistent with a previous report of a *lasR* overproducing *P. aeruginosa* strain found to be more resistant to ofloxacin, and in the absence of *lasR* (QS compromised), the overexpression of master regulator RpoS can restore the loss of ofloxacin resistance [90]. We also observe that lactonase treatment with GcL (but not SsoPox) increased its sensitivity towards norfloxacin (**Fig. 4**). This resonates with other studies reporting that the loss of function of the regulator protein NfxB, which represses the production of MexCD-OprJ efflux pump, is associated with increased resistance of *P. aeruginosa* against norfloxacin [91,92] and is under the regulatory control of the master regulator VqsM that promotes QS by producing LasI an (enzyme that synthesizes 3-oxo-C12-HSL in PA14) [93]. Additionally, lactonase-mediated QQ also had a synergistic effect when co-administered with the fluoroquinolone antibiotic ciprofloxacin and prevented the spread of *P. aeruginosa* in a burn wound infection model [30].

For other groups, such as β -lactams, alteration of QS modulation can either increase or decrease resistance. When AHL signaling is inhibited by lactonases, *P. aeruginosa* becomes more sensitive to nafcillin and oxacillin but more resistant to azlocillin and carbenicillin (**Fig. 4**).

This discrepancy is possibly a result of the use of different resistance mechanisms against these drugs. While *P. aeruginosa* strains were reported to produce β -lactamases such as AmpC [94] and OXA-50 [20] that offer protection against a broad range of β -lactam antibiotics, the resistance against some classes of β -lactam antibiotics can be mediated by the regulation of the expression of outer membrane porins and efflux pumps such as OprD and MexXY-OprM [95]. In support of this hypothesis, a previous proteomics study reported an increase in OprD and a decrease in OprM levels in PA14 upon AHL signal disruption using lactonases SsoPox W263I and GcL [59]. A synergy between nafcillin and QQ agents was also previously reported for Gram-positive pathogens – *Staphylococcus aureus* [96] and *Staphylococcus epidermidis* [97].

AHL-mediated quorum sensing and resistance of *P. aeruginosa* to sulfathiazole and trimethoprim.

Sulfathiazole and trimethoprim target the enzymes involved in the biosynthesis of folates in bacteria [98]. Sulfathiazole belongs to a class of compounds called sulfonamides that act as competitive inhibitors of the enzyme dihydropteroate synthase (DHPS; encoded by the *folP* gene in PA14). Trimethoprim, an antifolate compound, targets the enzyme dihydrofolate reductase (DHFR; encoded by the *folA* gene in PA14) [99]. While DHPS acts upstream of the folate biosynthesis pathway converting *p*-amino benzoic acid to dihydropteroate, DHFR is the enzyme catalyzing the terminal step of the pathway leading to the reduction of dihydrofolate to tetrahydrofolate [100]. Bacteria can develop resistance against sulfonamides or trimethoprim by using several mechanisms [101,102] - accumulation of compensatory mutations in the native DHPS/DHFR enzymes that prevent binding of the drugs [103,104], using drug efflux pumps and altering membrane barrier permeability [105,106], horizontal acquisition of foreign drug-resistant DHPS/DHFR variants or homologs either on the chromosome via mobile genetic elements or via plasmids [107,108], genetic regulation of DHPS/DHFR production [109,110], or producing specialized enzymes that cleave these drugs [111].

In this study, the modulations of the resistance to sulfonamide and trimethoprim observed in *P. aeruginosa* PA14 by QS are likely to originate from the genetic regulation of *folA* and *folP* genes. To test this hypothesis, we carried out qRT-PCR experiments to determine the expression levels of *folA* and *folP* transcript mRNA under a variety of conditions (**Fig. 5**). In the absence of any antibiotics, when QS is attenuated by lactonases, *folA* (**Fig. 5A**) and *folP* (**Fig. 5B**) genes are upregulated by 4-fold and 3-fold, respectively, compared to an inactive enzyme treated control. This suggests a possible increased metabolic demand for folate when QS is suppressed. When AHL signaling is attenuated and PA14 is challenged with sulfathiazole, expression of *folA* remains significantly upregulated (between 2 to 2.5-fold; **Fig. 5C**) compared to the inactive enzyme treated control. However, *folP* expression is downregulated by 30% (**Fig. 5D**). In the presence of trimethoprim, only *folP* expression is increased (2-fold, **Fig. 5F**) as compared to control. This downregulation of *folP* upon AHL signal disruption is also observed in the absolute levels of transcripts (**Fig. S13**). Under most conditions (**Fig. S13**), as expected, competitive inhibitors like sulfathiazole and trimethoprim increase the production of F_oIA and F_oIP enzymes, compared to the no-antibiotic control. However, when AHL signaling is disrupted by lactonases, the absolute *folP* levels in sulfathiazole treated PA14 are reduced to similar levels to those observed for untreated PA14.

These observations suggest that QS regulates the expression of *folP* and *folA* genes in PA14. We also observe that QQ leads to increased resistance of PA14 to sulfathiazole (**Fig. 5**). In a study previously conducted in yeast auxotrophs [109], sulfonamides, in addition to inhibiting DHPS, are metabolized to sulfa-dihydropteroate, a compound that inhibits the downstream enzyme DHFR and thereby the biosynthesis of folate. This inhibition can be thwarted by overproducing DHFR. When challenged with sulfathiazole and AHL signal disruption, we observed a simultaneous downregulation of *folP* (DHPS; **Fig. 5D**) and overproduction of *folA* (DHFR; **Fig. 5C**). This *folP* and *folA* regulation might explain the higher resistance of PA14 to sulfathiazole when QS is disrupted.

Unlike sulfathiazole, changes in resistance of PA14 against trimethoprim upon AHL signal disruption cannot be explained solely by the observed changes in *folP* and *folA* regulation. An increase in absolute (**Fig. S13**) and relative levels (compared to inactive lactonase 5A8 treatment, **Fig. 5F**) of *folP* in the presence of trimethoprim and lactonase can be observed, and it might contribute to the observed increased resistance (**Fig. 4**). Adaptive resistance mechanisms such as the regulation of efflux pumps might be involved in the QS-dependent regulation of trimethoprim resistance in PA14. For example, MexEF-OprN efflux pump overexpression (due to loss of function of its repressor NfxC) renders *P. aeruginosa* resistant to several antibiotics including trimethoprim [112]. Similarly, the BpeEF-OprC efflux pump system confers trimethoprim resistance to *Burkholderia pseudomallei* [113].

AHL signaling can modulate the potency of antibiotic treatments in a *P. aeruginosa* *C. elegans* infection model.

Upon observing that interference in AHL signaling modulates antibiotic resistance of *P. aeruginosa* in liquid cultures, we examined whether these modulations would translate into altered PA14 pathogenicity in an *in vivo* *Caenorhabditis elegans* infection model. *C. elegans* is a nematode whose genotypes and phenotypes have been characterized and have long served as a model organism in cellular, molecular, and developmental biology research [114,115]. It has also been extensively used as a convenient model animal host in a plethora of microbial infection assays [68,116-118]. We adapted the standard liquid killing assay (see methods section). Lactonases were previously shown to reduce the virulence of *P. aeruginosa* against *C. elegans* in infection assays [46].

When challenged with nafcillin or sulfathiazole, the pathogenicity of PA14 in a *C. elegans* killing assay is significantly modulated by AHL-based quorum sensing (**Fig. 6A, 6B**). For instance, in the presence of nafcillin (**Fig. 6A**) and sulfathiazole (**Fig. 6B**), QQ lactonase treatment reduced the virulence of PA14 against *C. elegans*. Nematode survival increased by

up to 34% and 150% for nafcillin and sulfathiazole respectively, upon treatment with SsoPox W263I and GcL compared to the inactive enzyme control. Conversely, with azlocillin, nematode mortality is increased by lactonase treatment by up to 81% compared to control (**Fig. 6C**).

Alteration of the antibiotic resistance profile of PA14 *in vivo* by AHL-based QS is further evidenced by the observed modulations of the nematode mortality upon treatment with AHL signaling molecules. For example, treatment of PA14 with sulfathiazole and 3oC12-HSL caused an increase in nematode mortality (+78%), whereas sulfathiazole and C4-HSL treatment led to an increase in survival (+138%), compared to an inactive lactonase treated control. This may suggest that the regulation of virulence, in the presence of sulfathiazole, is similar to that described for pyocyanin production. Indeed, Rhl QS circuit agonists like C4-HSL were reported to suppress pyocyanin production in *P. aeruginosa* in a PQS-dependent manner [119,120].

The changes in pathogenicity of PA14 against *C. elegans* upon treatment with nafcillin or azlocillin and QQ lactonases echo a trend observed in the PA14's resistance profile against these compounds. QQ lactonase treatment increased the sensitivity of PA14 to nafcillin (**Fig. 4**), and its virulence against *C. elegans* is also reduced in the presence of nafcillin (**Fig. 6A**). Similarly, the resistance of PA14 to azlocillin is increased upon treatment with QQ lactonases (**Fig. 4**), and accordingly, its virulence against *C. elegans* is increased in the presence of QQ lactonases and azlocillin (**Fig. 6C**). Unexpectedly, however, we observe that while the treatment with QQ lactonases increases the resistance of PA14 to sulfathiazole (**Fig. 4**), its virulence is reduced (**Fig. 6B**), suggesting that the relationship between antibiotic resistance and its ability to kill the nematodes can be complex.

Taken together, these observations show that AHL-based QS and signal disruption can alter the pathogenicity of *P. aeruginosa* against *C. elegans* in the presence of antibiotics. QQ lactonases can modulate the sensitivity of PA14 to an antibiotic in a manner that may not always be reflected in changes in its virulence under similar conditions. Therefore, it appears

that a combined administration of antibiotics and QQ agents can result in virulence changes that are difficult to predict and can either prove to be beneficial or detrimental to the host.

Conclusion

In this study, we demonstrate that the disruption of AHL-mediated QS signaling by the thermostable lactonases SsoPox and GcL can alter the antibiotic resistance profile of the Gram-negative pathogen *P. aeruginosa* PA14. This likely occurs *via* changes in the regulation of both intrinsic and adaptive resistance mechanisms. We were able to translate the observations from the Biolog Phenotype MicroArrays into experimental replicates using similar growth conditions for multiple antibiotics at their respective sublethal concentrations. Changes in antibiotic resistance against sulfathiazole and trimethoprim could be linked to key changes in the expression levels of genes involved in folate biosynthesis. Lastly, these observations were evaluated with an *in vivo* *C. elegans* infection model, and the results confirm that (i) the ability of *P. aeruginosa* to kill the nematode in presence of certain antibiotics depends on QS; (ii) yet that the combined effects of antibiotics and QQ lactonase are not always synergistic. Overall, whereas most previous studies investigating the effect of co-administration of QQ agents (QS inhibitors, enzymes) and antibiotics in bacterial infection models reported a positive synergistic effect [30,37,97], our results suggest that in *P. aeruginosa*, the relationship between antibiotics and QQ agents is very complex, and depends on the type of antibiotic and substrate preference of the QQ agent used. More studies are needed to decipher the mechanisms for the synergies and antagonisms described in this work to assess and evaluate the potential of combination therapy in *P. aeruginosa*.

Figure legends

Figure 1. PA14 growth profile for antimicrobials for which lactonase treatment increases sensitivity. Growth of PA14 in the presence of lactonases – SsoPox W263I (Sso) and GcL or exogenously added AHLs – C4-HSL (C4) and 3-oxo-C12-HSL (3oC12) is represented as a % of PA14 growth in the presence of inactive lactonase SsoPox 5A8 (control) with a white-red-black color scheme. Adjacent to it, an additional heat map strip with a green-black color scheme is overlaid, representing the relative resistance score (see Methods) on a % scale, and indicating the sensitivity of PA14 to the tested antibiotics and antibacterial compounds. Tested compounds are grouped according to their classes indicated on the left. Higher relative resistance scores indicate higher resistance of PA14. All lactonases and AHLs are used at 50 µg/mL and 10 µM final concentrations, respectively.

Figure 2. PA14 growth profile for antimicrobials for which lactonase treatment increases resistance. Growth of PA14 in the presence of lactonases – SsoPox W263I (Sso) and GcL or exogenously added AHLs – C4-HSL (C4) and 3-oxo-C12-HSL (3oC12) is represented as a % of PA14 growth in the presence of inactive lactonase SsoPox 5A8 (control) with a white-red-black color scheme. Adjacent to it, an additional heat map strip with a green-black color scheme is overlaid, representing the relative resistance score (see Methods) on a % scale, and indicating the sensitivity of PA14 to the tested antibiotics and antibacterial compounds. Tested compounds are grouped according to their classes indicated on the left. Higher relative resistance scores indicate higher resistance of PA14. All lactonases and AHLs are used at 50 µg/mL and 10 µM final concentrations, respectively.

Figure 3. Effects of AHL signal disruption on different classes of antimicrobials. Pie charts showing the fraction of tested compounds from different classes for which a change in sensitivity and/or resistance of PA14 upon AHL signal disruption is observed.

Figure 4. Replicated PA14 growth experiments in the presence of 10 antimicrobials identified in the screening experiment and interference in quorum sensing compounds.

Treatments are: QQ lactonases – SsoPox W263I (Sso) and GcL or exogenously added AHLs – C4-HSL (C4) and 3-oxo-C12-HSL (3oC12), compared to control treatment (inactive lactonase SsoPox 5A8 (5A8)). PA14 growth in all treatments is normalized to the respective 5A8 control. All lactonases and AHLs are used at 50 µg/mL and 10 µM final concentrations, respectively. Following concentration of antibiotics were used – 200 µg/mL nafcillin, 800 µg/mL oxacillin, 200 µg/mL D-cyclo-serine, 0.25 µg/mL norfloxacin, 0.5 µg/mL ofloxacin, 5 µg/mL azlocillin, 25 µg/mL sulfadiazine, 25 µg/mL sulfathiazole, 50 µg/mL carbenicillin and 20 µg/mL trimethoprim. All experiments were done, and all data is represented as the mean and standard deviation of at least triplicates. Statistical significance of all treatments compared to the control (5A8) was calculated using unpaired two-tailed t-tests with Welch's correction and significance values are indicated as - *** $p < 0.0005$, ** $p < 0.005$ and * $p < 0.05$.

Figure 5. Changes in mRNA levels (as measured by qRT-PCR) of genes *folA* and *folP* with sulfathiazole and trimethoprim and as a function of quorum sensing interference. Used treatments are no antibiotics (**A, B**) or with antibiotics sulfathiazole (**C, D**) and trimethoprim (**E, F**). Tested conditions include the QQ lactonases – SsoPox W263I (Sso) and GcL or exogenously added AHLs – C4-HSL (C4) and 3-oxo-C12-HSL (3oC12), compared to control treatment (inactive lactonase SsoPox 5A8 (5A8)). *folA* and *folP* mRNA levels in all treatments were determined using the relative quantification method using the *recA* gene as endogenous control and normalized to the respective 5A8 control, which is set to 1 on a log₂ scale. All

lactonases and AHLs were used at 50 µg/mL and 10 µM final concentrations, respectively. The following concentration of antibiotics was used – 25 µg/mL sulfathiazole and 20 µg/mL trimethoprim. All experiments were done, and all data is represented as the mean and standard deviation of at least triplicates. Statistical significance of all treatments compared to the control (5A8) was calculated using unpaired two-tailed t-tests with Welch's correction and significance values are indicated as - *** $p < 0.0005$, ** $p < 0.005$ and * $p < 0.05$.

Figure 6. *In vivo C. elegans* infection to evaluate the effects of the interference in quorum sensing and antibiotic treatments. Assays were performed with antibiotics – nafcillin (**A**), sulfathiazole (**B**) and azlocillin (**C**) upon treatment with QQ lactonases – SsoPox W263I (Sso) and GcL or exogenously added AHLs – C4-HSL (C4) and 3-oxo-C12-HSL (3oC12), compared to control treatment (inactive lactonase SsoPox 5A8 (5A8)). Virulence of PA14 is exemplified by the death of *C. elegans* upon infection. Mortality is represented as the % of nematodes that survived the assay. *E. coli* strain OP50 is used as a non-virulent control for the assays. All lactonases and AHLs are used at 100 µg/mL and 20 µM final concentrations, respectively. Used concentration of antibiotics were – 200 µg/mL nafcillin, 25 µg/mL sulfathiazole and 5 µg/mL azlocillin. All experiments were done, and all data is represented as the mean and standard deviation of at least triplicates. Statistical significance of all treatments compared to the control (5A8) was calculated using unpaired two-tailed t-tests with Welch's correction and significance values are indicated as - *** $p < 0.0005$, ** $p < 0.005$ and * $p < 0.05$.

Conflict of interest statement.

MHE is the co-founder, former Scientific Advisory Board member, and equity holder of Gene&Green TK, a company that holds the license to WO2014167140 A1, FR 3068989 A1, FR 19/02834. MHE has a patent No. 62/816,403. These interests have been reviewed and managed by the University of Minnesota in accordance with its Conflict-of-Interest policies. The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Acknowledgement.

We would like to thank Dr. Eliana Drenkard and Dr. Frederick Ausubel at the Massachusetts General Hospital for providing us with *Pseudomonas aeruginosa* strain PA14, Dr. Barry Bochner at Biolog Inc. for helping us setting up the experimental protocol with Biolog Phenotype MicroArrays and Aric Daul at the *Caenorhabditis* Genetics Center (CGC) at the University of Minnesota for providing us with *Caenorhabditis elegans* strain SS104 and *Escherichia coli* strain OP50. This work was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number R35GM133487. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References

1. Abdula N, Macharia J, Motsoaledi A, et al. National action for global gains in antimicrobial resistance. *Lancet*. 2016 Jan 9;387(10014):e3-5.
2. Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global crisis. *Infect Drug Resist*. 2018;11:1645-1658.
3. Hernando-Amado S, Coque TM, Baquero F, et al. Defining and combating antibiotic resistance from One Health and Global Health perspectives. *Nat Microbiol*. 2019 Sep;4(9):1432-1442.
4. Hsu J. How covid-19 is accelerating the threat of antimicrobial resistance. *BMJ*. 2020 May 18;369:m1983.
5. Pang Z, Raudonis R, Glick BR, et al. Antibiotic resistance in *Pseudomonas aeruginosa*: mechanisms and alternative therapeutic strategies. *Biotechnol Adv*. 2019 Jan - Feb;37(1):177-192.
6. Richards MJ, Edwards JR, Culver DH, et al. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. *Crit Care Med*. 1999 May;27(5):887-92.
7. Rossi E, La Rosa R, Bartell JA, et al. *Pseudomonas aeruginosa* adaptation and evolution in patients with cystic fibrosis. *Nat Rev Microbiol*. 2021 May;19(5):331-342.
8. Mogasale VV, Saldanha P, Pai V, et al. A descriptive analysis of antimicrobial resistance patterns of WHO priority pathogens isolated in children from a tertiary care hospital in India. *Sci Rep*. 2021 Mar 4;11(1):5116.
9. Abril D, Marquez-Ortiz RA, Castro-Cardozo B, et al. Genome plasticity favours double chromosomal Tn4401b-blaKPC-2 transposon insertion in the *Pseudomonas aeruginosa* ST235 clone. *BMC Microbiol*. 2019 Feb 20;19(1):45.
10. Silby MW, Winstanley C, Godfrey SA, et al. *Pseudomonas* genomes: diverse and adaptable. *FEMS Microbiol Rev*. 2011 Jul;35(4):652-80.
11. Rutherford ST, Bassler BL. Bacterial quorum sensing: its role in virulence and possibilities for its control. *Cold Spring Harb Perspect Med*. 2012 Nov 1;2(11).
12. Schuster M, Greenberg EP. A network of networks: quorum-sensing gene regulation in *Pseudomonas aeruginosa*. *International journal of medical microbiology : IJMM*. 2006 Apr;296(2-3):73-81.
13. Sikdar R, Elias M. Quorum quenching enzymes and their effects on virulence, biofilm, and microbiomes: a review of recent advances. *Expert Rev Anti Infect Ther*. 2020 Dec;18(12):1221-1233.
14. Lee J, Zhang L. The hierarchy quorum sensing network in *Pseudomonas aeruginosa*. *Protein Cell*. 2015 Jan;6(1):26-41.
15. Kostylev M, Kim DY, Smalley NE, et al. Evolution of the *Pseudomonas aeruginosa* quorum-sensing hierarchy. *Proc Natl Acad Sci U S A*. 2019 Apr 2;116(14):7027-7032.
16. Zemke AC, D'Amico EJ, Snell EC, et al. Dispersal of Epithelium-Associated *Pseudomonas aeruginosa* Biofilms. *mSphere*. 2020 Jul 15;5(4).
17. Williams P, Camara M. Quorum sensing and environmental adaptation in *Pseudomonas aeruginosa*: a tale of regulatory networks and multifunctional signal molecules. *Curr Opin Microbiol*. 2009 Apr;12(2):182-91.
18. Zhao X, Yu Z, Ding T. Quorum-Sensing Regulation of Antimicrobial Resistance in Bacteria. *Microorganisms*. 2020 Mar 17;8(3).
19. Langendonk RF, Neill DR, Fothergill JL. The Building Blocks of Antimicrobial Resistance in *Pseudomonas aeruginosa*: Implications for Current Resistance-Breaking Therapies. *Front Cell Infect Microbiol*. 2021;11:665759.

20. Girlich D, Naas T, Nordmann P. Biochemical characterization of the naturally occurring oxacillinase OXA-50 of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2004 Jun;48(6):2043-8.
21. Poole K. Aminoglycoside resistance in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2005 Feb;49(2):479-87.
22. Doi Y, Arakawa Y. 16S ribosomal RNA methylation: emerging resistance mechanism against aminoglycosides. *Clin Infect Dis*. 2007 Jul 1;45(1):88-94.
23. Ciofu O, Tolker-Nielsen T. Tolerance and Resistance of *Pseudomonas aeruginosa* Biofilms to Antimicrobial Agents-How *P. aeruginosa* Can Escape Antibiotics. *Front Microbiol*. 2019;10:913.
24. Baron S, Hadjadj L, Rolain JM, et al. Molecular mechanisms of polymyxin resistance: knowns and unknowns. *Int J Antimicrob Agents*. 2016 Dec;48(6):583-591.
25. Ude J, Tripathi V, Buyck JM, et al. Outer membrane permeability: Antimicrobials and diverse nutrients bypass porins in *Pseudomonas aeruginosa*. *Proc Natl Acad Sci U S A*. 2021 Aug 3;118(31).
26. Fernandez L, Gooderham WJ, Bains M, et al. Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in *Pseudomonas aeruginosa* is mediated by the novel two-component regulatory system ParR-ParS. *Antimicrob Agents Chemother*. 2010 Aug;54(8):3372-82.
27. Fernandez L, Jenssen H, Bains M, et al. The two-component system CprRS senses cationic peptides and triggers adaptive resistance in *Pseudomonas aeruginosa* independently of ParRS. *Antimicrob Agents Chemother*. 2012 Dec;56(12):6212-22.
28. Gooderham WJ, Hancock RE. Regulation of virulence and antibiotic resistance by two-component regulatory systems in *Pseudomonas aeruginosa*. *FEMS Microbiol Rev*. 2009 Mar;33(2):279-94.
29. Kiran S, Sharma P, Harjai K, et al. Enzymatic quorum quenching increases antibiotic susceptibility of multidrug resistant *Pseudomonas aeruginosa*. *Iran J Microbiol*. 2011 Mar;3(1):1-12.
30. Gupta P, Chhibber S, Harjai K. Efficacy of purified lactonase and ciprofloxacin in preventing systemic spread of *Pseudomonas aeruginosa* in murine burn wound model. *Burns*. 2015 Feb;41(1):153-62.
31. Mion S, Remy B, Plener L, et al. Quorum Quenching Lactonase Strengthens Bacteriophage and Antibiotic Arsenal Against *Pseudomonas aeruginosa* Clinical Isolates. *Front Microbiol*. 2019;10:2049.
32. Krzyzek P. Challenges and Limitations of Anti-quorum Sensing Therapies. *Front Microbiol*. 2019;10:2473.
33. Evans KC, Benomar S, Camuy-Velez LA, et al. Quorum-sensing control of antibiotic resistance stabilizes cooperation in *Chromobacterium violaceum*. *ISME J*. 2018 May;12(5):1263-1272.
34. Ning Q, Wang DL, You J. Joint effects of antibiotics and quorum sensing inhibitors on resistance development in bacteria. *Environ Sci-Proc Imp*. 2021 Jul 1;23(7):995-1005.
35. Shukla A, Shukla G, Parmar P, et al. Exemplifying the next generation of antibiotic susceptibility intensifiers of phytochemicals by LasR-mediated quorum sensing inhibition. *Sci Rep*. 2021 Nov 17;11(1):22421.
36. Skindersoe ME, Alhede M, Phipps R, et al. Effects of antibiotics on quorum sensing in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 2008 Oct;52(10):3648-63.
37. Remy B, Mion S, Plener L, et al. Interference in Bacterial Quorum Sensing: A Biopharmaceutical Perspective. *Front Pharmacol*. 2018;9:203.
38. Billot R, Plener L, Jacquet P, et al. Engineering acyl-homoserine lactone-interfering enzymes toward bacterial control. *J Biol Chem*. 2020 Sep 11;295(37):12993-13007.

39. Elias M, Tawfik DS. Divergence and convergence in enzyme evolution: parallel evolution of paraoxonases from quorum-quenching lactonases. *J Biol Chem*. 2012 Jan 2;287(1):11-20.
40. Hiblot J, Bzdrenga J, Champion C, et al. Crystal structure of VmoLac, a tentative quorum quenching lactonase from the extremophilic crenarchaeon *Vulcanisaeta moutnovskia*. *Sci Rep*. 2015 Feb 11;5:8372.
41. Hiblot J, Gotthard G, Chabriere E, et al. Structural and enzymatic characterization of the lactonase SisLac from *Sulfolobus islandicus*. *PLoS One*. 2012;7(10):e47028.
42. Afriat L, Roodveldt C, Manco G, et al. The latent promiscuity of newly identified microbial lactonases is linked to a recently diverged phosphotriesterase. *Biochemistry*. 2006 Nov 21;45(46):13677-86.
43. Elias M, Dupuy J, Merone L, et al. Structural basis for natural lactonase and promiscuous phosphotriesterase activities. *J Mol Biol*. 2008 Jun 20;379(5):1017-28.
44. Hiblot J, Gotthard G, Chabriere E, et al. Characterisation of the organophosphate hydrolase catalytic activity of SsoPox. *Sci Rep*. 2012;2:779.
45. Hiblot J, Gotthard G, Elias M, et al. Differential active site loop conformations mediate promiscuous activities in the lactonase SsoPox. *PLoS One*. 2013;8(9):e75272.
46. Tang K, Su Y, Brackman G, et al. MomL, a novel marine-derived N-acyl homoserine lactonase from *Muricauda olearia*. *Applied and environmental microbiology*. 2015 Jan;81(2):774-82.
47. Dong YH, Xu JL, Li XZ, et al. AiiA, an enzyme that inactivates the acylhomoserine lactone quorum-sensing signal and attenuates the virulence of *Erwinia carotovora*. *Proc Natl Acad Sci U S A*. 2000 Mar 28;97(7):3526-31.
48. Bergonzi C, Schwab M, Naik T, et al. Structural and Biochemical Characterization of AaL, a Quorum Quenching Lactonase with Unusual Kinetic Properties. *Sci Rep*. 2018 Jul 26;8(1):11262.
49. Bergonzi C, Schwab M, Naik T, et al. The Structural Determinants Accounting for the Broad Substrate Specificity of the Quorum Quenching Lactonase GcL. *Chembiochem*. 2019 Jul 15;20(14):1848-1855.
50. Bijtenhoorn P, Mayerhofer H, Muller-Dieckmann J, et al. A novel metagenomic short-chain dehydrogenase/reductase attenuates *Pseudomonas aeruginosa* biofilm formation and virulence on *Caenorhabditis elegans*. *PLoS One*. 2011;6(10):e26278.
51. Utari PD, Setroikromo R, Melgert BN, et al. PvdQ Quorum Quenching Acylase Attenuates *Pseudomonas aeruginosa* Virulence in a Mouse Model of Pulmonary Infection. *Front Cell Infect Microbiol*. 2018;8:119.
52. Lopez-Jacome LE, Garza-Ramos G, Hernandez-Duran M, et al. AiiM Lactonase Strongly Reduces Quorum Sensing Controlled Virulence Factors in Clinical Strains of *Pseudomonas aeruginosa* Isolated From Burned Patients. *Front Microbiol*. 2019;10:2657.
53. Anandan K, Vittal RR. Quorum quenching activity of AiiA lactonase KMMI17 from endophytic *Bacillus thuringiensis* KMCL07 on AHL- mediated pathogenic phenotype in *Pseudomonas aeruginosa*. *Microb Pathog*. 2019 Jul;132:230-242.
54. Guendouze A, Plener L, Bzdrenga J, et al. Effect of Quorum Quenching Lactonase in Clinical Isolates of *Pseudomonas aeruginosa* and Comparison with Quorum Sensing Inhibitors. *Front Microbiol*. 2017;8:227.
55. Hraiech S, Hiblot J, Lafleur J, et al. Inhaled lactonase reduces *Pseudomonas aeruginosa* quorum sensing and mortality in rat pneumonia. *PLoS One*. 2014;9(10):e107125.
56. Mahan K, Martinmaki R, Larus I, et al. Effects of Signal Disruption Depends on the Substrate Preference of the Lactonase. *Front Microbiol*. 2019;10:3003.

57. Papaioannou E, Wahjudi M, Nadal-Jimenez P, et al. Quorum-quenching acylase reduces the virulence of *Pseudomonas aeruginosa* in a *Caenorhabditis elegans* infection model. *Antimicrob Agents Chemother*. 2009 Nov;53(11):4891-7.
58. Pustelny C, Albers A, Buldt-Karentzopoulos K, et al. Dioxygenase-Mediated Quenching of Quinolone-Dependent Quorum Sensing in *Pseudomonas aeruginosa*. *Chem Biol*. 2009 Dec 24;16(12):1259-1267.
59. Remy B, Plener L, Decloquement P, et al. Lactonase Specificity Is Key to Quorum Quenching in *Pseudomonas aeruginosa*. *Front Microbiol*. 2020;11:762.
60. Schroth MN, Cho JJ, Green SK, et al. Epidemiology of *Pseudomonas aeruginosa* in agricultural areas(). *J Med Microbiol*. 2018 Aug;67(8):1191-1201.
61. LaBauve AE, Wargo MJ. Growth and laboratory maintenance of *Pseudomonas aeruginosa*. *Curr Protoc Microbiol*. 2012 May;Chapter 6:Unit 6E 1.
62. Jacquet P, Hiblot J, Daude D, et al. Rational engineering of a native hyperthermostable lactonase into a broad spectrum phosphotriesterase. *Sci Rep*. 2017 Dec 1;7(1):16745.
63. Remy B, Plener L, Poirier L, et al. Harnessing hyperthermostable lactonase from *Sulfolobus solfataricus* for biotechnological applications. *Sci Rep*. 2016 Nov 23;6:37780.
64. Bochner BR, Gadzinski P, Panomitros E. Phenotype microarrays for high-throughput phenotypic testing and assay of gene function. *Genome Res*. 2001 Jul;11(7):1246-55.
65. Bochner BR. New technologies to assess genotype-phenotype relationships. *Nat Rev Genet*. 2003 Apr;4(4):309-14.
66. Mackie AM, Hassan KA, Paulsen IT, et al. Biolog Phenotype Microarrays for phenotypic characterization of microbial cells. *Methods Mol Biol*. 2014;1096:123-30.
67. Kirienko NV, Kirienko DR, Larkins-Ford J, et al. *Pseudomonas aeruginosa* disrupts *Caenorhabditis elegans* iron homeostasis, causing a hypoxic response and death. *Cell Host Microbe*. 2013 Apr 17;13(4):406-16.
68. Kirienko NV, Cezairliyan BO, Ausubel FM, et al. *Pseudomonas aeruginosa* PA14 pathogenesis in *Caenorhabditis elegans*. *Methods Mol Biol*. 2014;1149:653-69.
69. Beanan MJ, Strome S. Characterization of a germ-line proliferation mutation in *C. elegans*. *Development*. 1992 Nov;116(3):755-66.
70. Scanlan LD, Lund SP, Coskun SH, et al. Counting *Caenorhabditis elegans*: Protocol Optimization and Applications for Population Growth and Toxicity Studies in Liquid Medium. *Sci Rep*. 2018 Jan 17;8(1):904.
71. Ismail NS, Subbiah SK, Taib NM. Application of Phenotype Microarray for Profiling Carbon Sources Utilization between Biofilm and Non-Biofilm of *Pseudomonas aeruginosa* from Clinical Isolates. *Curr Pharm Biotechnol*. 2020;21(14):1539-1550.
72. Johnson DA, Tetu SG, Phillippy K, et al. High-throughput phenotypic characterization of *Pseudomonas aeruginosa* membrane transport genes. *PLoS Genet*. 2008 Oct 3;4(10):e1000211.
73. Marvig RL, Dolce D, Sommer LM, et al. Within-host microevolution of *Pseudomonas aeruginosa* in Italian cystic fibrosis patients. *BMC Microbiol*. 2015 Oct 19;15:218.
74. Oberhardt MA, Puchalka J, Martins dos Santos VA, et al. Reconciliation of genome-scale metabolic reconstructions for comparative systems analysis. *PLoS Comput Biol*. 2011 Mar;7(3):e1001116.
75. Starkey M, Hickman JH, Ma L, et al. *Pseudomonas aeruginosa* rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung. *Journal of bacteriology*. 2009 Jun;191(11):3492-503.
76. Yang L, Jelsbak L, Marvig RL, et al. Evolutionary dynamics of bacteria in a human host environment. *Proceedings of the National Academy of Sciences of the United States of America*. 2011 May 3;108(18):7481-6.

77. De Majumdar S, Veleba M, Finn S, et al. Elucidating the regulon of multidrug resistance regulator RarA in *Klebsiella pneumoniae*. *Antimicrob Agents Chemother*. 2013 Apr;57(4):1603-9.
78. Mishra MN, Daniels L. Characterization of the MSMEG_2631 gene (mmp) encoding a multidrug and toxic compound extrusion (MATE) family protein in *Mycobacterium smegmatis* and exploration of its polyspecific nature using biolog phenotype microarray. *Journal of bacteriology*. 2013 Apr;195(7):1610-21.
79. Tocci N, Iannelli F, Bidossi A, et al. Functional analysis of pneumococcal drug efflux pumps associates the MATE DinF transporter with quinolone susceptibility. *Antimicrob Agents Chemother*. 2013 Jan;57(1):248-53.
80. Jałowiecki Ł, Chojniak J, Dorgeloh E, et al. Using phenotype microarrays in the assessment of the antibiotic susceptibility profile of bacteria isolated from wastewater in on-site treatment facilities. *Folia Microbiologica*. 2017 2017/11/01;62(6):453-461.
81. Qais FA, Khan MS, Ahmad I, et al. Coumarin Exhibits Broad-Spectrum Antibiofilm and Antiquorum Sensing Activity against Gram-Negative Bacteria: In Vitro and In Silico Investigation. *ACS Omega*. 2021 Jul 27;6(29):18823-18835.
82. Zhang Y, Sass A, Van Acker H, et al. Coumarin Reduces Virulence and Biofilm Formation in *Pseudomonas aeruginosa* by Affecting Quorum Sensing, Type III Secretion and C-di-GMP Levels. *Front Microbiol*. 2018;9:1952.
83. Laborda P, Alcalde-Rico M, Blanco P, et al. Novel Inducers of the Expression of Multidrug Efflux Pumps That Trigger *Pseudomonas aeruginosa* Transient Antibiotic Resistance. *Antimicrob Agents Chemother*. 2019 Nov;63(11).
84. Singh VK, Mishra A, Jha B. Anti-quorum Sensing and Anti-biofilm Activity of *Delftia tsuruhatensis* Extract by Attenuating the Quorum Sensing-Controlled Virulence Factor Production in *Pseudomonas aeruginosa*. *Front Cell Infect Microbiol*. 2017;7:337.
85. Blondeau JM. Fluoroquinolones: mechanism of action, classification, and development of resistance. *Surv Ophthalmol*. 2004 Mar;49 Suppl 2:S73-8.
86. Blair JM, Webber MA, Baylay AJ, et al. Molecular mechanisms of antibiotic resistance. *Nat Rev Microbiol*. 2015 Jan;13(1):42-51.
87. Li XZ, Nikaido H, Poole K. Role of mexA-mexB-oprM in antibiotic efflux in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 1995 Sep;39(9):1948-53.
88. Morita Y, Komori Y, Mima T, et al. Construction of a series of mutants lacking all of the four major mex operons for multidrug efflux pumps or possessing each one of the operons from *Pseudomonas aeruginosa* PAO1: MexCD-OprJ is an inducible pump. *FEMS Microbiol Lett*. 2001 Aug 7;202(1):139-43.
89. Sobel ML, Neshat S, Poole K. Mutations in PA2491 (mexS) promote MexT-dependent mexEF-oprN expression and multidrug resistance in a clinical strain of *Pseudomonas aeruginosa*. *Journal of bacteriology*. 2005 Feb;187(4):1246-53.
90. Kayama S, Murakami K, Ono T, et al. The role of rpoS gene and quorum-sensing system in ofloxacin tolerance in *Pseudomonas aeruginosa*. *FEMS Microbiol Lett*. 2009 Sep;298(2):184-92.
91. Hirai K, Suzue S, Irikura T, et al. Mutations producing resistance to norfloxacin in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 1987 Apr;31(4):582-6.
92. Masuda N, Gotoh N, Ohya S, et al. Quantitative correlation between susceptibility and OprJ production in NfxB mutants of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother*. 1996 Apr;40(4):909-13.
93. Liang H, Deng X, Li X, et al. Molecular mechanisms of master regulator VqsM mediating quorum-sensing and antibiotic resistance in *Pseudomonas aeruginosa*. *Nucleic Acids Res*. 2014;42(16):10307-20.

94. Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant *Pseudomonas aeruginosa*: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. *Clin Microbiol Rev.* 2009 Oct;22(4):582-610.
95. Petrova A, Feodorova Y, Miteva-Katrandzhieva T, et al. First detected OXA-50 carbapenem-resistant clinical isolates *Pseudomonas aeruginosa* from Bulgaria and interplay between the expression of main efflux pumps, OprD and intrinsic AmpC. *J Med Microbiol.* 2019 Dec;68(12):1723-1731.
96. Kuo D, Yu G, Hoch W, et al. Novel quorum-quenching agents promote methicillin-resistant *Staphylococcus aureus* (MRSA) wound healing and sensitize MRSA to beta-lactam antibiotics. *Antimicrob Agents Chemother.* 2015 Mar;59(3):1512-8.
97. Pammi M, Liang R, Hicks JM, et al. Farnesol decreases biofilms of *Staphylococcus epidermidis* and exhibits synergy with nafcillin and vancomycin. *Pediatr Res.* 2011 Dec;70(6):578-83.
98. Bourne CR. Utility of the Biosynthetic Folate Pathway for Targets in Antimicrobial Discovery. *Antibiotics (Basel).* 2014 Jan 21;3(1):1-28.
99. Fernandez-Villa D, Aguilar MR, Rojo L. Folic Acid Antagonists: Antimicrobial and Immunomodulating Mechanisms and Applications. *Int J Mol Sci.* 2019 Oct 9;20(20).
100. Bermingham A, Derrick JP. The folic acid biosynthesis pathway in bacteria: evaluation of potential for antibacterial drug discovery. *Bioessays.* 2002 Jul;24(7):637-48.
101. Skold O. Sulfonamide resistance: mechanisms and trends. *Drug Resist Updat.* 2000 Jun;3(3):155-160.
102. Huovinen P. Resistance to trimethoprim-sulfamethoxazole. *Clin Infect Dis.* 2001 Jun 1;32(11):1608-14.
103. Levy C, Minnis D, Derrick JP. Dihydropteroate synthase from *Streptococcus pneumoniae*: structure, ligand recognition and mechanism of sulfonamide resistance. *Biochem J.* 2008 Jun 1;412(2):379-88.
104. Manna MS, Tamer YT, Gaszek I, et al. A trimethoprim derivative impedes antibiotic resistance evolution. *Nat Commun.* 2021 May 19;12(1):2949.
105. Kohler T, Kok M, Michea-Hamzehpour M, et al. Multidrug efflux in intrinsic resistance to trimethoprim and sulfamethoxazole in *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 1996 Oct;40(10):2288-90.
106. Maseda H, Yoneyama H, Nakae T. Assignment of the substrate-selective subunits of the MexEF-OprN multidrug efflux pump of *Pseudomonas aeruginosa*. *Antimicrob Agents Chemother.* 2000 Mar;44(3):658-64.
107. Jiang H, Cheng H, Liang Y, et al. Diverse Mobile Genetic Elements and Conjugal Transferability of Sulfonamide Resistance Genes (*sul1*, *sul2*, and *sul3*) in *Escherichia coli* Isolates From *Penaeus vannamei* and Pork From Large Markets in Zhejiang, China. *Front Microbiol.* 2019;10:1787.
108. Miranda A, Avila B, Diaz P, et al. Emergence of Plasmid-Borne *dfrA14* Trimethoprim Resistance Gene in *Shigella sonnei*. *Front Cell Infect Microbiol.* 2016;6:77.
109. Patel O, Karnik K, Macreadie IG. Over-production of dihydrofolate reductase leads to sulfa-dihydropteroate resistance in yeast. *FEMS Microbiol Lett.* 2004 Jul 15;236(2):301-5.
110. Tamer YT, Gaszek IK, Abdizadeh H, et al. High-Order Epistasis in Catalytic Power of Dihydrofolate Reductase Gives Rise to a Rugged Fitness Landscape in the Presence of Trimethoprim Selection. *Mol Biol Evol.* 2019 Jul 1;36(7):1533-1550.
111. Kim DW, Thawng CN, Lee K, et al. A novel sulfonamide resistance mechanism by two-component flavin-dependent monooxygenase system in sulfonamide-degrading actinobacteria. *Environ Int.* 2019 Jun;127:206-215.

112. Kohler T, Michea-Hamzehpour M, Henze U, et al. Characterization of MexE-MexF-OprN, a positively regulated multidrug efflux system of *Pseudomonas aeruginosa*. *Mol Microbiol.* 1997 Jan;23(2):345-54.
113. Podnecky NL, Wuthiekanun V, Peacock SJ, et al. The BpeEF-OprC efflux pump is responsible for widespread trimethoprim resistance in clinical and environmental *Burkholderia pseudomallei* isolates. *Antimicrob Agents Chemother.* 2013 Sep;57(9):4381-6.
114. Girard LR, Fiedler TJ, Harris TW, et al. WormBook: the online review of *Caenorhabditis elegans* biology. *Nucleic Acids Res.* 2007 Jan;35(Database issue):D472-5.
115. Kaletta T, Hengartner MO. Finding function in novel targets: *C. elegans* as a model organism. *Nat Rev Drug Discov.* 2006 May;5(5):387-98.
116. Jayamani E, Rajamuthiah R, Larkins-Ford J, et al. Insect-derived cecropins display activity against *Acinetobacter baumannii* in a whole-animal high-throughput *Caenorhabditis elegans* model. *Antimicrob Agents Chemother.* 2015 Mar;59(3):1728-37.
117. Durai S, Pandian SK, Balamurugan K. Establishment of a *Caenorhabditis elegans* infection model for *Vibrio alginolyticus*. *J Basic Microbiol.* 2011 Jun;51(3):243-52.
118. Chua SL, Liu Y, Yam JK, et al. Dispersed cells represent a distinct stage in the transition from bacterial biofilm to planktonic lifestyles. *Nat Commun.* 2014 Jul 21;5:4462.
119. Boursier ME, Combs JB, Blackwell HE. N-Acyl L-Homocysteine Thiolactones Are Potent and Stable Synthetic Modulators of the RhIR Quorum Sensing Receptor in *Pseudomonas aeruginosa*. *ACS Chem Biol.* 2019 Feb 15;14(2):186-191.
120. Welsh MA, Eibergen NR, Moore JD, et al. Small molecule disruption of quorum sensing cross-regulation in *pseudomonas aeruginosa* causes major and unexpected alterations to virulence phenotypes. *J Am Chem Soc.* 2015 Feb 4;137(4):1510-9.

Fig. 1





Fig. 2






Fig. 3




Fig. 4




Fig. 5




Fig. 6